唾液氨基酶响应的口腔药片可以消除化疗根源的耐火性口腔粘膜炎
Yan Zhang1, Taixia Wang1, Xiulin Dong2
1Department of Medical Ultrasound and Department of Stomatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Tongji University, NO. 301 Yan-chang-zhong Road, Shanghai, 200072, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 16, 2024
概括
新的口腔药片通过释放抗炎药物来有效治疗口腔粘膜炎 (OM),以应对唾液氨酶. 这种创新方法改善了患者的舒适性,并加速了化疗副作用的愈合.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 口腔粘膜炎 (OM) 是癌症治疗的严重副作用,严重影响患者的生活质量和治疗坚持.
- 现有的OM传递系统往往会引起不适,导致不良的合规性和不理想的治疗结果.
研究的目的:
- 设计新型的唾液氨酶响应的口腔药片,用于有效治疗口腔粘膜炎.
- 开发一种药物输送系统,以提高患者的舒适性和服药性,同时提高治疗疗效.
主要方法:
- 孔隙替代普鲁士蓝 (PMPB) 纳米立方体的开发,作为阿普雷米拉斯的药物载体 (Apr).
- 整合一种粉控制器,用于酶触发的,持续的药物释放,以应对唾液氨酶 (SAs).
- 在临床前模型中评估PMPB纳米立方体的ROS清除和抗炎性质,以及口腔片的整体疗效.
主要成果:
- PMPB纳米立方体有效地加载并释放了premilast,表现出模仿多酶的活性,以清除活性氧物种 (ROS).
- 粉控制器促进了连锁,连续的药物释放,由唾液氨酶触发,增强组织亲和力和用户舒适性.
- 临床前研究表明,口腔药片显著减轻了炎症,促进了内皮细胞的修复,并在化疗诱导的OM中加速了伤口愈合.
结论:
- 工程化唾液氨酶响应的口腔片为管理难治性口腔粘膜炎提供了一个有希望的策略.
- PMPB纳米立方体和apremilast的组合,与酶触发释放,提供了一个舒适和有效的治疗选择.
- 这种创新的交付系统显示了临床转化有很大的潜力,以改善癌症治疗患者的结果.
相关概念视频
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
490
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
490
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
205
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
205
01:23Salivary Glands and Saliva
689
The salivary glands, of which there are three pairs known as the parotid, submandibular, and sublingual glands, play a crucial role in maintaining oral health and initiating the digestive process. Positioned near the ears, beneath the masseter muscle, the parotid glands secrete saliva into the oral cavity through the parotid duct of Stensen. Meanwhile, the submandibular glands, located on the floor of the mouth, secrete saliva through channels named submandibular ducts. The sublingual glands,...
689
01:18Drug Delivery: Enteral Route
456
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
456
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
01:26Peptic Ulcer Disease IV: Management
94
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
94